These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 4208713)

  • 41. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
    Roberts D; Peck C; Hilliard S; Wingo W
    Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radioimmunoassay of 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T; Moffatt JG
    Methods Enzymol; 1982; 84():470-83. PubMed ID: 7098963
    [No Abstract]   [Full Text] [Related]  

  • 44. Protection of mice against lethal doses of 1 beta-D-arabinofuranosylcytosine by pluripotent stem cell inhibitors.
    Guigon M; Mary JY; Enouf J; Frindel E
    Cancer Res; 1982 Feb; 42(2):638-41. PubMed ID: 7055808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simultaneous determination of 6-azacytidine, 6-azauridine, arabinoside cytosine and arabinoside uracil in blood by liquid chromatography.
    Galushko SV; Shishkina IP
    J Pharm Biomed Anal; 1992; 10(10-12):1093-5. PubMed ID: 1284337
    [No Abstract]   [Full Text] [Related]  

  • 46. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
    Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
    Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the conjugate between N4-(4-carboxybutyryl)-1-beta-D-arabinofuranosylcytosine and chitosan as a macromolecular prodrug of 1-beta-D-arabinofuranosylcytosine.
    Ichikawa H; Onishi H; Takahata T; Machida Y; Nagai T
    Drug Des Discov; 1993; 10(4):343-53. PubMed ID: 8148473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolism of 1-beta-D-arabinofuranosylcytosine in leukemia L1210: nucleoside and nucleotide kinases in cell-free extracts.
    Schrecker AW
    Cancer Res; 1970 Mar; 30(3):632-41. PubMed ID: 5425288
    [No Abstract]   [Full Text] [Related]  

  • 50. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Hug V; Keating MJ; Chubb S
    Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis of 1-(3-deoxy-beta-D-psicofuranosyl)uracil and related compounds.
    Holý A
    Nucleic Acids Res; 1974 Feb; 1(2):289-98. PubMed ID: 4370426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Purines and purine nucleoside antagonists.
    LePage GA
    Transplant Proc; 1973 Sep; 5(3):1157-60. PubMed ID: 4199576
    [No Abstract]   [Full Text] [Related]  

  • 53. Increasing 1-beta-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics.
    Ubezio P; Tagliabue G; Schechter B; Agur Z
    Cancer Res; 1994 Dec; 54(24):6446-51. PubMed ID: 7987841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical studies with 1 beta-D-arabinofuranosylcytosine in human leukemic leukocytes and normal bone marrow cells.
    Creasey WA; DeConti RC; Kaplan SR
    Cancer Res; 1968 Jun; 28(6):1074-81. PubMed ID: 5241767
    [No Abstract]   [Full Text] [Related]  

  • 55. Cytotoxicity of N4-behenoyl-1-beta-D-arabinofuranosylcytosine through gradual conversion to 1-beta-D-arabinofuranosylcytosine in HeLa cells.
    Maehara Y; Kusumoto T; Sakaguchi Y; Kusumoto H; Anai H; Sugimachi K
    Anticancer Res; 1989; 9(1):41-4. PubMed ID: 2705754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Membrane affinity and metabolism of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine into cultured KB cells.
    Tsuruo T; Iida H; Hori K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1981 Nov; 41(11 Pt 1):4484-8. PubMed ID: 7306971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Studies on the tissue distribution and the gastro-intestinal absorption of 1- -D-arabinofuranosylcytosine].
    Ono Y; Tatewaki N; Okita A; Katsura Y
    Yakugaku Zasshi; 1972 May; 92(5):592-8. PubMed ID: 5066315
    [No Abstract]   [Full Text] [Related]  

  • 59. Two chromatographic methods for determination of cytarabine and dexamethazone; two co-administered drugs for the treatment of leukemia: green analytical perspective.
    Magdy MA; Elgebaly AM; Taha AA; Ali NW; Farid NF
    BMC Chem; 2024 May; 18(1):88. PubMed ID: 38698444
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential analysis of cyclocytidine, 1-beta-D-arabinofuranosylcytosine, and 1-beta-D-arabinofuranosyluracil by ultraviolet spectophotometry.
    Furner RL; Gaston RW; Strobel JD; el-Dareer S; Mellett LB
    J Natl Cancer Inst; 1974 May; 52(5):1521-8. PubMed ID: 4208713
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.